Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca - LARVOL DELTA

P109 Lebrikizumab for the treatment of moderate-to-severe atopic eczema: real-world experience from a tertiary centre. (PubMed, Br J Dermatol) - "Ten patients experienced ocular symptoms while on dupilumab (n = 8) or tralokinumab (n = 3). Moreover, lebrikizumab serves as a viable alternative for patients who experienced ocular complications with previous biologic therapies. Further long-term follow-up is essential in larger cohorts to fully assess the future role of lebrikizumab."

Journal • Real-world evidence • Retrospective data • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Dry Eye Disease • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • IL13

P113 JAK in the box: unlocking real-world factors influencing Janus kinase inhibitor and dupilumab prescribing in atopic dermatitis. (PubMed, Br J Dermatol) - "A retrospective review was carried out of patients aged ≥ 12 years prescribed dupilumab or a JAKi (upadacitinib, abrocitinib or baricitinib) for AD in our tertiary dermatology centre between 2021 and 2024. Tralokinumab and lebrikizumab were excluded as all patients had prior dupilumab...Factors favouring dupilumab prescribing include older age, asthma status and cardiovascular risk factors. Factors favouring JAKi prescribing included speed of onset, ease of prescribing, younger age and needle phobia."

Journal • Real-world evidence • Retrospective data • Alopecia • Asthma • Atopic Dermatitis • Cardiovascular • Dermatitis • Dermatology • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hypertension • Immunology • Inflammation • Inflammatory Bowel Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Pulmonary Disease • Respiratory Diseases • Thrombosis • STAT2

P088 Janus kinase inhibitor treatment in coexisting atopic dermatitis and irritable bowel disease: real-world experience and therapeutic outcomes. (PubMed, Br J Dermatol) - "Despite the apparent efficacy treating IBD in this series, only two of seven patients (29%) achieved satisfactory cutaneous response to JAKi monotherapy, contrasting with established efficacy data in isolated AD. These findings raise questions about underlying disease mechanisms in this phenotype, warranting further investigation.TableTreatment of seven patients with atopic dermatitis (AD) and irritable bowel disease (IBD) with Janus kinase inhibitors (JAKis)Age (years)Primary indicationBefore JAKi treatmentOn JAKi treatmentDisease statusAD treatmentIBD treatmentJAKi therapyOutcomes50ADEASI 54; UC controlledNoneGuselkumab (stopped)Upadacitinib 24 months (ongoing)EASI 75 achieved (5.1); UC remission22AD, CDEASI 41; CD activeMethotrexate (stopped)Infliximab (stopped)Upadacitinib 4 months (ongoing)EASI 75 achieved (7.4); CD remission29ADEASI 13; UC controlledNoneAZA, allopurinol (stopped)Upadacitinib 8 months (ongoing)EASI 10.3; added methotrexate (6 months), switched to..."

Journal • Real-world evidence • Alopecia • Atopic Dermatitis • Crohn's disease • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Herpes Zoster • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • Varicella Zoster

P093 Switching patients who developed arthritis and/or enthesitis on dupilumab to tralokinumab: a case series. (PubMed, Br J Dermatol) - "Patient 2 developed bilateral shoulder, left Achilles tendon and back pain 2 years into dupilumab, which resolved when he switched to abrocitinib. To our knowledge, this is the first retrospective case series to report tralokinumab-associated inflammatory arthritis. These cases suggest that patients who develop arthritis or enthesitis on dupilumab are likely to experience similar symptoms on tralokinumab, and a treatment class switch (specifically to a Janus kinase inhibitor) can be beneficial.TablePatient characteristics Patient 1Patient 2Patient 3SexFemaleMaleFemaleAge (years)557028Eczema Area and Severity Index Baseline (pretreatment)23.630.329.5 On tralokinumab (month)6.1 (6)29.6 (4)2.1 (4)Arthropathy pattern Small joints+++ Large joints++-Enthesitis/tenosynovitis+++Ultrasound+N/A+CRP/ESRNormalN/ARaisedConcurrent managementNSAIDsN/ANSAIDsDuration of tralokinumab (months)13724Musculoskeletal symptom progressionImprovingResolvedImprovingTherapy after..."

Journal • Atopic Dermatitis • Back Pain • Dermatitis • Dermatology • Immunology • Inflammation • Inflammatory Arthritis • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Rheumatology • CRP • IL13

P117 Treatment and investigation of head and neck dermatitis in patients with atopic dermatitis treated with biologic and small-molecule therapies: a systematic review. (PubMed, Br J Dermatol) - "Improved/resolved HND was not reported per patient, but in one trial, the median time to 75% improvement in HND was 57 days for dupilumab (n = 238) vs. 29 days for abrocitinib 200 mg...Adverse HND was also reported for tralokinumab (3 of 49, 6%) and baricitinib (two of three, 67%)...Itraconazole led to clinical improvement in all cases that recurred on withdrawal...Future studies should compare head and neck outcomes between different biologics and JAKis. This will help improve treatment decisions for patients where HND is of particular concern."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

BI27 Treatment of recalcitrant eczema in a patient with B-cell and natural killer cell lymphopenia of unknown cause. (PubMed, Br J Dermatol) - "He had tried superpotent topical corticosteroids and oral prednisolone, as well as emollients, none of which had improved his symptoms...Tralokinumab was trialled for 12 weeks, as this has a single therapeutic target (interleukin-13), but unfortunately there was no improvement. Following discussion with the immunologists, he was commenced on upadacitinib as this was felt to have a more targeted immunosuppressive effect above agents such as methotrexate and dupilumab. We await his next follow-up appointment to assess response. This case highlights the complexity of treating an immunocompromised individual with immunosuppressive agents, when the cause of their immunosuppression is unknown."

Journal • Atopic Dermatitis • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Herpes Zoster • Immunology • Infectious Disease • Mycosis Fungoides • Oncology • Solid Tumor • Thymoma • Thymus Cancer • Varicella Zoster • BTK • GATA2 • IL13

P106 Real-world experience of the efficacy and safety of tralokinumab use in atopic dermatitis: a multicentre audit. (PubMed, Br J Dermatol) - "Minor infections or viral illnesses were likely under-reported at follow-up, although there were no serious infections. Longer-term follow-up will provide further evidence of efficacy and safety outside of trial settings."

Journal • Real-world evidence • Retrospective data • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Dry Eye Disease • Immunology • Infectious Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • IL13

P012 Metastatic Staphylococcus aureus bacteraemia in atopic dermatitis: a case series. (PubMed, Br J Dermatol) - "IV, intravenousPatientClinical manifestationsComplications of SABTreatment of metastatic SABOutcome1Diaphoresis, rigors, nausea, fatigueMitral/aortic valve IE8 weeks IV flucloxacillinRecommenced on methotrexate; good control of AD2ErythrodermaMitral valve IE6 weeks IV flucloxacillinCommenced on dupilumab; excellent control of AD3Pyrexia and rigors following abscess development at footMitral/aortic valve IE6 weeks IV cefazolinMitral valve repair for mitral regurgitation. Recent commencement of dupilumab; AD improving4Erythroderma, subjective fevers, fatigueMRSA bacteraemia with mitral valve IETotal duration 6 weeks 6 days: IV vancomycin → IV daptomycin → IV ceftaroline + vancomycin → oral linezolidRecent recommencement of tralokinumab; AD improving5Right shoulder painSeptic arthritis of right shoulderIV flucloxacillin + vancomycin → 8 weeks daptomycin + rifampicin → 6 weeks doxycyclineCommenced on dupilumab; excellent control of ADAD, atopic dermatitis; IE, infective..."

Journal • Atopic Dermatitis • Cardiovascular • Cognitive Disorders • Dermatitis • Dermatology • Dermatopathology • Immunology • Infectious Disease • Inflammation • Musculoskeletal Pain • Pain • Rheumatology

Preclinical development of an anti-IL-13 antibody for the treatment of atopic dermatitis (ISDS 2025) - "Type 2 inflammatory pathway antagonism is safe and effective in the treatment of atopic dermatitis, with multiple approved drugs targeting the cytokine IL-13 (Ebglyss, Adbry) or its receptor IL-4R (Dupixent), and other IL-13 antagonists showing success in clinical development with half-life extended molecules (APG777). These molecules demonstrate pM IL-13 affinity, efficient antagonism of IL-13 signaling in both reporter cell lines and primary keratinocytes, extended half-life properties, and manufacturability and stability profiles consistent with commercially validated therapeutics. These candidates open the door to synergistic combinations pairing IL-13 antagonism with complementary pathway inhibition, for the treatment of inflammatory diseases like atopic dermatitis, particularly addressing patients whose disease remains inadequately controlled by existing systemic therapies."

Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • IL13 • IL4R

Tralokinumab effectiveness in moderate-to-severe atopic dermatitis with palmoplantar eczema. (PubMed, Actas Dermosifiliogr) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Impact of type 2-targeted therapies on respiratory infection risk. (PubMed, Curr Opin Allergy Clin Immunol) - "T2-modulating biologics not only control allergic inflammation but also restore epithelial and immune homeostasis, contributing to maintained or reduced respiratory infection risk. These therapies represent a dual benefit of barrier repair and immune rebalancing. Further studies are warranted to evaluate long-term infection outcomes in high-risk populations."

Journal • Allergy • Infectious Disease • Inflammation • Respiratory Diseases • IL13 • IL4 • IL5

Lebrikizumab for the Treatment of Moderate to Severe Atopic Eczema: Real-World Experience from a Tertiary Centre. (PubMed, Dermatol Ther (Heidelb)) - "In this real-world cohort of patients with atopic dermatitis, lebrikizumab demonstrated efficacy comparable to that observed in clinical trials. It may provide an alternative treatment option for individuals who have discontinued other biologics as a result of conjunctivitis."

Journal • Real-world evidence • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • IL13

Development of a psoriatic arthritis - like presentation under anti - IL-13 therapy with tralokinumab for atopic dermatitis. (PubMed, Rheumatology (Oxford)) - "To our knowledge, this is the first case series documenting arthritis and enthesitis associated with anti-IL-13 therapy, suggesting a potential pathogenetic role of IL-13 inhibition in the development of PsA-like presentation. These findings warrant further investigation."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL13 • IL17A • IL23A • IL4

Successful Use of Tralokinumab in a Pediatric Patient With STAT3 Hyper-IgE Syndrome Following Dupilumab-Associated Conjunctivitis. (PubMed, Int J Dermatol) - No abstract available

Journal • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology • STAT3

Transitioning from Cyclosporine to Tralokinumab in Moderate-to-Severe Atopic Dermatitis: A Prospective Real-World Comparison of Direct Switch vs. Short Overlap. (PubMed, J Pers Med) - "In light of CSA's risks, TM may be considered a reasonable first-line systemic option. Prospective randomized studies are needed to determine whether overlap confers additional benefit."

Journal • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • IL13

LEO Pharma Announces Positive Topline 32-Week Key Results in ADHAND Trial (The AI Journal) - "The trial met all key primary and secondary endpoints at Week 16 as well as all endpoints at Week 32, including efficacy on extent and severity of disease, itch, pain, sleep, and health-related quality of life and the safety and tolerability of continued tralokinumab treatment...At Week 16, tralokinumab also achieved a statistically significant reduction in both itch and pain versus placebo..."

P3 data • Atopic Dermatitis

Systemic Therapies for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: A Systematic Review. (PubMed, Cureus) - "Dupilumab and tralokinumab (biologics) demonstrated significant efficacy, with Eczema Area and Severity Index 75 (EASI-75) response rates of 43.3% at week 16 and sustained improvements in disease severity (SCORAD, IGA) and pruritus. The JAK inhibitors, abrocitinib and upadacitinib, showed rapid and high-magnitude efficacy, with EASI-75 and Validated Investigator Global Assessment (vIGA-AD) response rates frequently exceeding 70-90% by weeks 12-16 and providing rapid itch relief...Biologics offer a well-established safety profile, while JAK inhibitors provide superior and faster efficacy, particularly for itch, but require careful safety monitoring. Treatment choice should be individualized based on disease severity, preference, and risk profile."

Journal • Review • Acne Vulgaris • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • Pediatrics • Pruritus

Tralokinumab for moderate-to-severe atopic dermatitis: A viable option for dupilumab nonresponders. (PubMed, JAAD Int) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Basophils in Atopic Dermatitis: Immunologic Roles and Clinical Implications. (PubMed, Ann Allergy Asthma Immunol) - "Additionally, therapies such as dupilumab, tralokinumab, and nemolizumab which target IL-4, IL-13 and IL-31 respectively, likely exert part of their effect by modulating basophil activity. In this review, we summarize the immunologic functions of basophils in AD pathogenesis, discuss their relevance as biomarkers and therapeutic targets, and outline future directions for integrating basophil-focused strategies in the management of patients with AD."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Eosinophilia • Immunology • Inflammation • Pruritus • IL13 • IL4

Real-World Effectiveness of Biologic Treatments for Moderate-to-Severe Atopic Dermatitis in Poland in Comparison With Efficacy Reported in Clinical Trials (ISPOR-EU 2025) - "The effectiveness of five biologics (abrocitinib, baricitinib, dupilumab, tralokinumab, upadacitinib) was assessed with proportion of patients reaching 75% improvement in the Eczema Area and Severity Index (EASI75) and proportion of 0 or 1 scores on Dermatology Life Quality Index (DLQI 0/1). In real-world settings in Poland, biologic treatments for moderate-to-severe atopic dermatitis show higher effectiveness than observed in clinical trials."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Assessment of Real-World Effectiveness of Biologic Treatments for Moderate-to-Severe Atopic Dermatitis in Poland (ISPOR-EU 2025) - "The effectiveness of five biologics, namely abrocitinib, baricitinib, dupilumab, tralokinumab, and upadacitinib, was assessed with proportion of patients reaching 75% improvement in the Eczema Area and Severity Index (EASI75) and proportion of 0 or 1 scores on Dermatology Life Quality Index (DLQI 0/1). After 16 weeks, the percentage of patients achieving EASI75 ranged from 69% (baricitinib) to 81% (tralokinumab). In real-world settings in Poland, different biologic agents show high, but differing effectiveness in treating moderate-to-severe atopic dermatitis. The data from the drug program indicate similar effectiveness across all included treatments in EASI75 and varying results in DLQI 0/1 response."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Forecasting Uptake of Novel Drugs Used for Atopic Dermatitis in Sweden Based on Historic RWE (ISPOR-EU 2025) - "The objective of this study was to forecast the number of patients with AD on each respective treatment (januskinase [JAK] inhibitors abrocitinib, baricitinib, upadacitinib; interleukin inhibitors dupilumab, tralokinumab) over the next five-year period, nationally and in the six Health Care Regions. Individual level drug dispensation data were obtained from the Swedish Prescribed Drug Registry between January 2018 and April 2025. The number of patients receiving novel AD treatments in Sweden is projected to increase substantially over next five years, creating additional health gains at a reasonable cost per patient. Accumulated treatment costs will be substantial, but optimizing treatment choice could limit the costs while further increasing the total incremental net benefit."

Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

Characteristics of Patients Treated With Biologic Agents for Moderate-to-Severe Atopic Dermatitis in Poland (ISPOR-EU 2025) - "The conditions of the B.124 drug program underwent significant changes over the years of its operation. The overall baseline characteristics of the patients were similar across the different treatments."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitis. (PubMed, J Eur Acad Dermatol Venereol) - P3 | "These data suggest that tralokinumab plus optional TCS/TCI provides long-term stable disease control, equivalent to no-to-mild disease, in a subgroup of adults with moderate-to-severe AD who completed 1 year of treatment in parent trials and up to 3 years in ECZTEND."

Journal • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • Pruritus • Respiratory Diseases • IL13

Cost-Effectiveness Analysis of Lebrikizumab vs. Alternative Biologics in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis in the UK (ISPOR-EU 2025) - "Biologics (lebrikizumab, dupilumab, tralokinumab) and JAK inhibitors are recommended by NICE and the Scottish Medicines Consortium for treating moderate-to-severe AD in patients that are not suitable for or have not responded to at least one systemic immunosuppressant. Commercial arrangements add further value to real world incremental costs and lebrikizumab is considered cost-effective against alternative biologics and was recommended for reimbursement by UK HTA agencies in AD patients that are not suitable for or have not responded to at least one systemic immunosuppressant. Lebrikizumab generates more QALYs than comparator biologics."

Clinical • Cost effectiveness • HEOR • Atopic Dermatitis • Dermatitis • Dermatology • Immunology